AU2019236860B2 - Organic compounds - Google Patents

Organic compounds Download PDF

Info

Publication number
AU2019236860B2
AU2019236860B2 AU2019236860A AU2019236860A AU2019236860B2 AU 2019236860 B2 AU2019236860 B2 AU 2019236860B2 AU 2019236860 A AU2019236860 A AU 2019236860A AU 2019236860 A AU2019236860 A AU 2019236860A AU 2019236860 B2 AU2019236860 B2 AU 2019236860B2
Authority
AU
Australia
Prior art keywords
disorder
compound
compounds
agonist
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019236860A
Other languages
English (en)
Other versions
AU2019236860A1 (en
Inventor
Robert Davis
Peng Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of AU2019236860A1 publication Critical patent/AU2019236860A1/en
Application granted granted Critical
Publication of AU2019236860B2 publication Critical patent/AU2019236860B2/en
Priority to AU2025200857A priority Critical patent/AU2025200857A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019236860A 2018-03-23 2019-03-22 Organic compounds Active AU2019236860B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025200857A AU2025200857A1 (en) 2018-03-23 2025-02-07 Organic compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647482P 2018-03-23 2018-03-23
US62/647,482 2018-03-23
PCT/US2019/023687 WO2019183546A1 (en) 2018-03-23 2019-03-22 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025200857A Division AU2025200857A1 (en) 2018-03-23 2025-02-07 Organic compounds

Publications (2)

Publication Number Publication Date
AU2019236860A1 AU2019236860A1 (en) 2020-10-22
AU2019236860B2 true AU2019236860B2 (en) 2024-11-14

Family

ID=67987581

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019236860A Active AU2019236860B2 (en) 2018-03-23 2019-03-22 Organic compounds
AU2025200857A Pending AU2025200857A1 (en) 2018-03-23 2025-02-07 Organic compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025200857A Pending AU2025200857A1 (en) 2018-03-23 2025-02-07 Organic compounds

Country Status (12)

Country Link
US (1) US20210008065A1 (https=)
EP (1) EP3768271B1 (https=)
JP (2) JP2021519271A (https=)
CN (1) CN112088004A (https=)
AU (2) AU2019236860B2 (https=)
BR (1) BR112020019181A2 (https=)
CA (1) CA3095101A1 (https=)
DK (1) DK3768271T3 (https=)
FI (1) FI3768271T3 (https=)
IL (2) IL303857B2 (https=)
MX (1) MX2020009929A (https=)
WO (1) WO2019183546A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305990B2 (en) * 2013-12-03 2025-12-01 Intra Cellular Therapies Inc Long-acting injectable composition comprising polymeric microspheres of heterocycle fused gamma-carboline compounds or a pharmaceutical composition for sustained or delayed release comprising the compounds and their use in the treatment of bipolar disorder i and/or bipolar ii disorder
CN108883111B (zh) 2016-01-26 2021-10-08 细胞内治疗公司 有机化合物
IL268970B2 (en) 2017-03-24 2023-12-01 Intra Cellular Therapies Inc Oral transmucosal formulations of substituted heterocycle fused gamma carbolines
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN111107847A (zh) 2017-09-26 2020-05-05 细胞内治疗公司 新的盐和晶体
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
AU2019240226B2 (en) 2018-03-23 2024-11-28 Intra-Cellular Therapies, Inc. Organic compounds
CA3106447A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
CN112584837A (zh) 2018-08-31 2021-03-30 细胞内治疗公司 新方法
CA3108558A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
IL283963B2 (en) 2018-12-17 2025-01-01 Intra Cellular Therapies Inc Synthesis of condensed gamma-carbolines and converted heterocycles
WO2020132605A1 (en) 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compounds
JP7673040B2 (ja) 2019-07-07 2025-05-08 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
EP4034119A4 (en) 2019-09-25 2023-10-18 Intra-Cellular Therapies, Inc. NOVEL METHODS
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
JP7533361B2 (ja) * 2021-05-26 2024-08-14 株式会社三洋物産 遊技機
JP2025521115A (ja) 2022-05-18 2025-07-08 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
EP4665344A1 (en) 2023-02-17 2025-12-24 Intra-Cellular Therapies, Inc. Lumateperone and derivatives thereof for modulating the nervous system
WO2025111568A1 (en) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
WO2025240804A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices and methods
WO2025257090A1 (en) 2024-06-10 2025-12-18 Interquim, S.A. Process for the preparation of synthesis intermediates of lumateperone and lumateperone analogues

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
WO2000035419A2 (en) 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
MXPA01012969A (es) 1999-06-15 2003-10-14 Bristol Myers Squibb Pharma Co Gamma-carbolinas fusionadas de heterociclo sustituido.
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
KR100699516B1 (ko) 2002-07-29 2007-03-26 알자 코포레이션 팔리페리돈의 조절 전달을 위한 방법 및 복용 형태
KR102065319B1 (ko) 2007-03-12 2020-01-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
JP5611846B2 (ja) 2008-03-12 2014-10-22 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 置換ヘテロ環縮合ガンマ−カルボリン類固体
CN105168219B (zh) 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
EP2560676B8 (en) 2010-04-22 2016-10-12 Intra-Cellular Therapies, Inc. Organic compounds
WO2013155504A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel methods
SG11201501894VA (en) * 2012-09-14 2015-04-29 Abbvie Inc Tricyclic quinoline and quinoxaline derivatives
MX365969B (es) * 2014-04-04 2019-06-21 Intra Cellular Therapies Inc Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
RU2016143091A (ru) * 2014-04-04 2018-05-08 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2017117514A1 (en) 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
PL3407889T3 (pl) 2016-03-25 2021-11-22 Intra-Cellular Therapies, Inc. Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego

Also Published As

Publication number Publication date
EP3768271A4 (en) 2021-11-17
IL303857B2 (en) 2024-08-01
IL277509A (en) 2020-11-30
EP3768271A1 (en) 2021-01-27
IL303857B1 (en) 2024-04-01
IL277509B2 (en) 2023-11-01
AU2025200857A1 (en) 2025-02-27
AU2019236860A1 (en) 2020-10-22
WO2019183546A1 (en) 2019-09-26
CN112088004A (zh) 2020-12-15
BR112020019181A2 (pt) 2021-01-05
IL303857A (en) 2023-08-01
DK3768271T3 (da) 2026-03-02
MX2020009929A (es) 2021-01-08
US20210008065A1 (en) 2021-01-14
FI3768271T3 (fi) 2026-03-30
EP3768271B1 (en) 2026-02-18
IL277509B1 (en) 2023-07-01
JP2024123211A (ja) 2024-09-10
CA3095101A1 (en) 2019-09-26
JP2021519271A (ja) 2021-08-10

Similar Documents

Publication Publication Date Title
AU2019236860B2 (en) Organic compounds
US12269825B2 (en) Organic compounds
CA3016353C (en) Deuterated fused heterocycle gamma-carbolines and compositions thereof useful in the treatment of nervous system disorders
WO2017165755A1 (en) Organic compounds
HK1233542A1 (en) Deuterated heterocycle fused gamma-carbolines as antagonists of 5-ht2a receptors
HK1233542B (en) Deuterated heterocycle fused gamma-carbolines as antagonists of 5-ht2a receptors
HK40000220B (en) Organic compounds and their use in treating or preventing central nervous system disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)